Fluorescent micrograph demonstrating that lung mesenchymal stem cells transdifferentiate to contractile NG-2 expressing pericytes in vitro.
Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy

Adriano R. Tonelli1, Sarah Haserodt2, Metin Aytekin3, and Raed A. Dweik1,2

1Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, 2Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA; and 3Department of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Turkey

ABSTRACT

Nitric oxide (NO) is a diffusible gas with diverse roles in human physiology and disease. Significant progress in the understanding of its biological effects has taken place in recent years. This has led to a better understanding of the pathobiology of pulmonary hypertension (PH) and the development of new therapies. This article provides an overview of the NO physiology and its role in the pathobiology of lung diseases, particularly PH. We also discuss current and emerging specific treatments that target NO signaling pathways in PH.

Key Words: pulmonary hypertension, nitric oxide, physiopathology and therapeutics

Pulmonary arterial hypertension (PAH) is a progressive disease that has poor prognosis since it may lead to right ventricular failure and death. The disease is characterized by excessive pulmonary vasoconstriction and abnormal vascular remodeling that result in loss of vascular cross-sectional area and increase in right ventricular afterload. One of the proposed mechanisms involved in the pathogenesis of the disease is an imbalance in vasoactive mediators with reduced levels of the vasodilatory and antiproliferative nitric oxide (NO).

Since the breakthrough discovery in 1987 that the endothelium-derived relaxing factor was nitric oxide (NO), this colorless and odorless free-radical gas became increasingly recognized as a key factor in human physiology and disease. NO is an autocrine and paracrine signaling molecule whose functions are diverse and involve smooth muscle relaxation, platelet inhibition, central and autonomic neurotransmission, tumor cell lysis, bacterial killing, and stimulation of hormonal release. This review will focus on the role of NO in physiology and pathobiology of lung diseases, particularly pulmonary hypertension (PH), and the current and emerging pulmonary hypertension (PH)-specific treatments based on NO signaling.

Nitric oxide (NO) is an endogenously synthesized, diffusible, lipophilic gas that is produced by a group of enzymes known as nitric oxide synthases (NOS). Their role is to convert the amino acid L-arginine to L-citrulline and NO. For their activity, NOS require oxygen, reduced nicotinamide-adenine dinucleotide phosphate (NADPH), and other cofactors such as flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), calmodulin, and tetrahydrobiopterin (BH4). NOS is active as a homodimer and contains a reductase and an oxygenase domain. The oxygenase domain is the active site of NO synthesis with binding sites for heme, L-arginine, and BH4 (Fig. 1). Three NOS isoforms (Types I, II, and III) have been identified. These NOS isoforms have important differences in expression and regulation as shown in Table 1.

In general, NOS I is expressed in neuronal cells and skeletal muscle; NOS II is found in epithelial, and smooth muscles cells as well as in neutrophils, macrophages, and fibroblasts; and NOS III is present in endothelial cells throughout the body. NOS I and III are continuously expressed and regulated by Calcium/Calmodulin; meanwhile, NOS II is...
Table 1: Characteristics of nitric oxide synthases isoforms

<table>
<thead>
<tr>
<th>NOS isoforms</th>
<th>Designation</th>
<th>Size (KDa)</th>
<th>Expression</th>
<th>Main cellular sources in the lung</th>
<th>Calcium regulation</th>
<th>Nitric oxide output</th>
<th>Chromosome</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Neural NOS (nNOS)</td>
<td>155</td>
<td>Constitutive</td>
<td>Inhibitory non-adrenergic non-cholinergic nerves</td>
<td>Dependent</td>
<td>Picomolar</td>
<td>12</td>
</tr>
<tr>
<td>II</td>
<td>Inducible NOS (iNOS)</td>
<td>125</td>
<td>Inducible by cytokines, endotoxin and oxidants</td>
<td>Airway epithelial cells</td>
<td>Independent</td>
<td>Nanomolar</td>
<td>17</td>
</tr>
<tr>
<td>III</td>
<td>Endothelial NOS (eNOS)</td>
<td>135</td>
<td>Constitutive</td>
<td>Endothelial cells and brush border of ciliated epithelial cells</td>
<td>Dependent</td>
<td>Picomolar</td>
<td>7</td>
</tr>
</tbody>
</table>

NOS: nitric oxide synthase

Regulated at the transcription level. NOS II transcription is increased by cytokines (e.g., TNF-α, interferon-γ, and IL-1β), endotoxins, oxidants, and shear stress,[10,18] and is decreased by corticosteroids, retinoids, transforming growth factor beta, platelet-derived growth factor, insulin-like growth factor 1, and thrombin.[9,10,13,19] The initial clear distinction between the constitutive and inducible isoforms has been recently distorted and constitutive isoforms may be induced, and vice versa.[20,21]

NOS I acts as a functional antagonist of acetylcholine and mediates inhibitory nonadrenergic non-cholinergic neural bronchodilation.[22] NOS II is involved in inflammation as it mediates the cytotoxic activity of activated macrophages and may be a contributing factor in the vasodilation observed in septic shock.[23] NOS III plays a role in the regulation of vascular flow[24] and may reduce plasma exudation in the airways[25] and regulate ciliary beating and mucociliary clearance.[26] NOS III is the predominant source of NO production in the pulmonary circulation.[14,20] Studies in transgenic mice and humans to assess the relative contribution of the three NOS isoforms showed that NOS II and III are the key regulators of the pulmonary circulation tone. NOS III is the key mediator of resting tone through endothelium-dependent pulmonary vasculature vasodilation,[27] while NOS II may mediate the pulmonary circulation’s response to oxygen.[28] Targeted disruption of the NOS III gene in mice was associated with mild PH while NOS II may mediate the pulmonary vasculature remodeling[29] which likely reflects compensation by the other NOS isoforms.

Vascular smooth muscle and endothelial cells have the ability to regenerate the NOS substrate L-arginine by synthesizing argininosuccinate from citrulline and aspartate, a process that requires two enzymes, argininosuccinate synthase and argininosuccinate lyase.[30-32] The first enzyme is co-induced with NOS II and the second is constitutively expressed in these cells.[33] Exogenous citrulline administration effectively stimulated NO production in vascular endothelial cells by means of regenerating arginine.[31]

Once NO is produced, it may act within the cell in which it is generated or freely diffuse into adjacent cells (e.g., vascular smooth muscle cells), acting as an intra- or intercellular messenger.[9,34] The NO intracellular diffusion may be limited because NO is readily oxidized to the more stable metabolic products nitrite (NO$_2^-$) and nitrate (NO$_3^-$) and is scavenged predominantly by hemoglobin. Upon entering the cells, NO activates the intracellular soluble guanylate cyclase (sGC) to produce 3',5'-cyclic guanosine monophosphate (cGMP), which mediates most of the physiological and pathological effects of NO (Fig. 1).[10,35]

Two main types of guanylate cyclase (GC) are known: the particulate-associated enzymes, which are transmembrane receptors that contain GC that is activated by atrial and brain natriuretic peptide; and the cytosolic or soluble type which is activated by NO.[36,37] NO appears to exert its effect by binding to the heme iron (ferrous state) of the sGC, stimulating the enzyme basal cyclase activity several hundred-fold.[31,34,38] Once cGMP is produced, it mediates physiologic responses through its effects in cGMP-gated ion channels, cGMP-regulated phosphodiesterases, or cGMP-dependent protein kinases.[34,39] A preferential activation of specific target proteins is believed to
underlie the differential effects of cGMP in various cells. The cGMP signal is chiefly limited by phosphodiesterases (PDE) which degrade the cyclic nucleotide of GMP. PDE degrade both cyclic adenosine monophosphate (cAMP) and cGMP; however, PDE-5 is specific to cGMP, and indeed the enzyme requires the binding of cGMP for full activation.

NOS inhibitors and NO generators have allowed for a better understanding of the NO signaling pathways. NOS inhibitors are analogs of L-arginine that act as a false substrate for this enzyme and inhibit both the constitutive and inducible forms of NOS. Of these, the most widely used include N-monomethyl-L-arginine (L-NMMA), N-nitro-L-arginine (L-NNA), and N-nitro-L-arginine methyl ester (L-NAME). Another commonly utilized NOS inhibitor is L-aminoguanidine, a more selective inhibitor of NOS II. NO generators are compounds that release NO such as diethylamine, sodium nitroprusside, and isosorbide dinitrite, among others.

The most important endogenous NOS inhibitor among the methylated arginines is the asymmetric dimethylarginine (ADMA). ADMA is produced as a result of proteolysis of methylated proteins. The methylation of arginine is a post-translational modification via protein arginine methyltransferases (PRMT). ADMA acts as a false substrate and competitively inhibits NOS activity, blocking the formation of endogenous NO. ADMA undergoes clearance by the dimethylarginine dimethylaminohydrolase (DDAH) and it is also partially cleared by the kidneys. Methylated arginines, like ADMA, may be responsible for the “L-arginine paradox.” At physiological state, NOS is saturated with arginine, thus an increase in arginine concentration in plasma or cytosol should have no effect in NO production. However, elevating plasma arginine or citrulline levels enhance NO production, suggesting some form of competitive inhibition of NOS, such as ADMA, is present and can be overcome by increasing the arginine concentration. Another explanation for the arginine paradox is the potential existence of a separated cellular pool of arginine allocated to NO synthesis, i.e., caveolar-localized arginine regeneration system, in which citrulline is recycled to arginine. This hypothesis is supported by a study that revealed the colocalization in discrete cellular domains (caveolae) of enzymes involved in arginine regeneration and NO production.

**NITRIC OXIDE PHYSIOLOGY IN THE PULMONARY VASCULATURE**

The specific role of NO produced in the pulmonary vasculature is still a matter of intense investigation. Data suggest that NO inhibits smooth muscle tone, proliferation, and migration. NO causes relaxation of the vascular smooth muscle tone via the activation of cGMP. In fact, endogenous NO plays a key role in decreasing the pulmonary artery resistance at the time of birth and in maintaining the dilation of the pulmonary vasculature. The production of NO by NOS II in injured vascular smooth muscle cells may prevent vasospasm and inhibit cell proliferation by possibly inducing apoptosis. In addition, NO in this setting may regulate the metabolism of vascular smooth muscle cells, favoring anaerobic glycolysis, and lead to toxic effects on adjacent endothelial cells.

NO inhibits vascular smooth muscle cell proliferation, DNA synthesis, and collagen production via activation of cGMP. Furthermore, NO inhibits vascular smooth muscle cell migration independent of the effects on proliferation. Higher levels of NO are required to inhibit proliferation rather than to produce vasodilation, suggesting a potential concomitant activation by cGMP of the cAMP kinase pathway which inhibits cellular proliferation. NO generators can also inhibit proliferation in cells that lack sGC, suggesting that cGMP-independent mechanisms play a role. One of these potential mechanisms is the up regulation of Fas, a membrane protein that belongs to the TNF receptor family and induces apoptosis. NO-induced apoptosis could be the result of a feedback control on calcium responses to growth factors, or deamination of purine and pyrimidine bases in DNA that leads to increased mutagenesis and DNA strand breaks. Although NO has been reported to inhibit cell proliferation in endothelial cells, other investigations have shown that either exogenous NO or NO produced by NOS II in vascular smooth muscle cells may stimulate endothelial cell proliferation.

Alternative NO pathways include the oxidation of NO to form nitrite or reaction with protein thiols to form S-nitrosothiols, molecules that can lead to vasodilation or can regulate protein function by post-translational modification. NO is oxidized in the blood and tissues to form nitrite and nitrate. Nitrate is produced by the reaction of NO with oxyhemoglobin, while nitrite is formed by oxidation of NO. These molecules can be recycled to form NO by an allosterically controlled nitrite reductase reaction predominantly during hypoxia, thereby complementing the NOS pathway. Deoxygenated hemoglobin has nitrite reductase activity, forming NO from nitrate and nitrite that can explain the hypoxia-specific vasodilatory effect observed in
some organs. The NOS pathway is oxygen dependent while the nitrate-nitrite-NO pathway is hypoxia activated.\(^{[8,70]}\)

In addition, NO can be responsible for nitrosylation of a cysteine residue of the β-subunit of hemoglobin, resulting in S-nitrosylated-hemoglobin, a protein that exerts NO-like vasodilator effects.\(^{[39]}\) This reaction is favored in the oxygenated state of hemoglobin, and, once desaturation of hemoglobin occurs, there is release of SNO to acceptor thiols potentially delivering NO to the systemic circulation.\(^{[72]}\)

S-nitrosylation and nitration enable the systemic transport of the NO signal, a process that would not be possible for NO due to its very short half-life\(^{[14]}\) and strong affinity to bind hemoglobin.

### NITRIC OXIDE AND NITRIC OXIDE SYNTHASES IN THE LUNG

NO is produced endogenously in the human lung in the upper and lower respiratory tract and it is detectable in exhaled breath (6-8 ppb).\(^{[28,73]}\) The origin of exhaled NO in the human lung likely depends upon all three isoforms of NOS (I-III) but predominantly derives from the airway epithelial expression of NOS II, the high-producer of NO. NO metabolites like nitrosothiol and nitrite (NO\(_{2}^{-}\)) are found in the bronchoalveolar lavage of human lungs.\(^{[8]}\) NO is formed in high concentrations in the upper respiratory tract (nasopharynx and paranasal sinuses) and in lower quantities in the lower respiratory tract.\(^{[28,73]}\) It is produced in a variety of cells including epithelial, endothelial, and smooth muscle cells, and also in inhibitory non-adrenergic non-cholinergic neurons, mastocytes, fibroblasts, macrophages, lymphocytes, and neutrophils.\(^{[6,7,28]}\)

Immunohistochemical studies have identified the presence of all three isoforms of NOS, expressed in different cells of the human lung (Table 1).\(^{[6,10,12,28,74-76]}\) Specifically, NOS I is located in inhibitory non-adrenergic non-cholinergic neurons; NOS II is expressed in the airway epithelium; and NOS III is found in endothelial cells.\(^{[8,21,76,77]}\) Contrary to what occurs in other organs where NOS II needs to be induced, in the lungs this enzyme is continuously expressed in the airway epithelium at basal conditions.\(^{[21]}\)

NO is involved in pulmonary neurotransmission, host defense, airway and vascular smooth muscle relaxation, mucociliary clearance, airway mucus secretion, inflammation, and cytotoxicity.\(^{[8,77]}\) NO plays key roles in lung biology and has been implicated in the pathophysiology of several lung diseases such as asthma, cystic fibrosis, bronchopulmonary dysplasia, lymphangioleiomyomatosis, and adult respiratory distress syndrome in addition to pulmonary hypertension.\(^{[8,12,20,28,35,78-84]}\)

Endogenous NO plays an important role in the regulation of airway function, having both beneficial and detrimental effects.\(^{[80]}\) It leads to bronchial smooth muscle relaxation, potentially modulating the basal airway tone.\(^{[8]}\) Inhaled NO decreased pulmonary airway resistance in pigs and NO generators relaxed human airway smooth muscle in vitro.\(^{[8]}\) Exhaled NO is increased in inflammatory airway diseases such as asthma and bronchiectasis likely due to an increase in NOS II expression in the epithelial cells of these patients with some contribution from the constitutive NOS isoforms.\(^{[8,20,77]}\) In asthma the fraction of exhaled NO is considered a surrogate for eosinophilic airway inflammation and steroid responsiveness.\(^{[20,85-87]}\) A reduction in exhaled NO levels is observed in smokers possibly as a result of a dysregulation of NOS activity as cigarette smoke contains high levels of NO.\(^{[77,88]}\)

NO is a key molecule in the oxidative metabolism since it can exert oxidant or antioxidant effects depending on the local tissue milieu. Hence, in an environment where the load of antioxidant is low, NO will have oxidant properties; however, when the oxidant load is high, NO plays an antioxidant role by scavenging free radicals and reactive oxygen species.\(^{[16,74]}\) NO rapidly consumes superoxide (O\(_{2}^{-}\)) by forming peroxynitrite (ONOO\(^{-}\)) which is a less reactive oxidant that can be further metabolized to products like nitrate (NO\(_{3}^{-}\)).\(^{[79]}\) Some of these reactive oxygen species could be responsible for oxidative modification of cellular proteins such as oxidation of sGC, a reaction that can impair the specific activity of sGC and reduce the ability of NO to stimulate cGMP.\(^{[89]}\) On the same lines, recombinant human superoxide dismutase decreases oxidative stress and increases eNOS activity and expression, stimulating NO production, and ultimately pulmonary vasodilatation.\(^{[90-92]}\)

### NITRIC OXIDE IN PULMONARY HYPERTENSION

NO is a potent pulmonary vasodilator that is produced locally in the lung and has effects on smooth muscle relaxation and proliferation. The close proximity of the airways and vessels in the lung allows NO produced in high levels in the upper\(^{[93]}\) and lower\(^{[28]}\) airways by NOS II to affect pulmonary vascular tone, in concert with the low NO levels that are produced by NOS III in the vascular endothelium.\(^{[35]}\) NO is considered to be a selective pulmonary vasodilator because after exerting its vasodilator action, NO is scavenged by hemoglobin having minimal effects on systemic hemodynamics.\(^{[35]}\)

Disruption of the NO pathway is a major contributor to the pathobiology of PH. NO in exhaled breath and NO biochemical reaction products in bronchoalveolar lavage are lower in lungs of patients with PAH than controls and their level is inversely related to the degree of PH.\(^{[45,94]}\) NO
in exhaled breath of individuals with idiopathic PAH is significantly lower than subject with PH associated with other causes or healthy nonsmoking controls. In fact, patients with PH associated with other causes had similar levels of exhaled NO than healthy controls.

Early data demonstrated a reduced expression of NOS III, measured by immunostaining, in the vascular endothelium of pulmonary arteries in patients with PAH. This reduced expression inversely correlated with the severity of the morphological arterial changes. More recently, however, other investigators showed increased or unaltered NOS III immunostaining in PH. Moreover, there is evidence of high NOS III expression in plexiform lesions in PAH. A unifying hypothesis suggested that the activity of NOS III may be reduced rather than its expression. Other NOS isoforms besides NOS III may contribute to the low exhaled NO observed in idiopathic PAH.

NO has also been implicated in the important role that bone morphogenetic protein receptor II (BMPRII) has in the pathogenesis of PAH. In the lung, BMPRII is highly expressed in endothelial cells and its activation promotes proliferation, migration, and survival of these cells. BMPRII levels are markedly reduced in patients with heritable or idiopathic PAH, promoting endothelial dysfunction and apoptosis. These effects have been recently attributed to a decrease in NOS III activity, since BMPRII ligands failed to stimulate NOS III dependent protein kinase activation in pulmonary artery endothelial cells from patients with mutation in the BMPR2 gene.

PAH patients treated with epoprostenol had a three-fold higher exhaled NO than PH patients not receiving this treatment and two-fold higher than healthy controls. Interestingly, exhaled NO increased at 24 hours in those patients treated with this prostacyclin analog. These data suggest that prostacyclin analogs may in part improve PH through effects on NO. In support of this, previous work has shown that nebulized epoprostenol increased the exhaled NO in patients with PAH associated with congenital heart disease. Similarly, inhaled iloprost also led to an increase in NO concomitant with a decrease in pulmonary artery pressure in a patient with PAH associated with scleroderma. Other PAH-specific therapies that do not directly target the NO pathway may also improve the fraction of exhaled nitric oxide suggesting a crosstalk between different signaling pathways.

The NO signaling pathways have been found to be affected in PH at different levels. Endogenous NOS III inhibitors may be involved in the pathogenesis of PH. These include the symmetric and asymmetric dimethylarginines (ADMA). Animal models of hypoxic PH showed increased ADMA levels and decrease in activity of dimethylarginine dimethylaminohydrolase (DDAH), the endothelial enzyme that metabolizes ADMA. Higher serum levels of ADMA are increased in patients with idiopathic PAH and chronic thromboembolic pulmonary hypertension and correlate with disease severity and survival. ADMA levels increase predominantly due to a reduction in the expression and function DDAH.

Arginase II, an enzyme that is part of the urea cycle and breaks down arginine to ornithine, can decrease the substrate available to NOS for NO synthesis. Idiopathic and PAH associated with sickle cell disease patients have been found to have higher levels of Arginase II and lower levels of L-arginine than healthy controls. In the absence of L-arginine or BH4, NOS III may become “uncoupled,” resulting in the generation of the free radical superoxide.

**CLINICAL IMPLICATIONS IN PH: DIAGNOSIS AND PROGNOSIS**

Although the vascular endothelium produces large amounts of NO, very little is exhaled as a result of the marked affinity of NO to hemoglobin in the pulmonary circulation. In spite of this potential limitation, NO can be measured in exhaled breath and its concentration is inversely related to the exhalation flow. For this reason, the fraction of exhaled NO is measured at a constant flow (usually 50 mL/s). Using this approach, the fraction of exhaled NO is a reliable surrogate of the maximal flux of NO from the large airway compartment. This method does not measure the steady-state mean distal airway/alveolar concentration of NO. There is no simple surrogate for measuring this parameter since its determination requires the measurement of the fraction of exhaled NO at multiple expiratory flow rates and the application of a modified “slope-intercept” algorithm.

Authors have investigated whether exhaled NO could serve as a noninvasive marker of severity of disease and response to therapy in PH. The value of repetitive exhaled NO measurements was studied in 17 PAH patients over two years. NO levels at entry were inversely correlated with the number of months from the PAH diagnosis, suggesting a global decrease in NO over longer periods with the disease. Lower exhaled NO levels at entry were associated with higher pulmonary artery pressures and less decrease over time. NO at the beginning of the study was not associated with survival; nevertheless, its level increased over time in the PAH individuals who survived to complete the study when compared to those who died, and correlated with changes in pulmonary artery pressures. Thus,
exhaled NO could be a useful marker of disease severity and response to therapy.\textsuperscript{[94,95,106]}

Inhaled NO is frequently used for acute vasodilator challenge during right heart catheterization in patients with PAH. A positive pulmonary vasodilator test (decrease in mean pulmonary artery pressure of at least 10 mmHg to an absolute value less than 40 mmHg without decrease in cardiac output) indicates the patient that can potentially benefit from long-term calcium-channel blockers.\textsuperscript{[115-118]} NO vasodilator challenge in several types of PH can also provide prognostic information, as responders may have better outcome, independent of the treatment administered.\textsuperscript{[119-122]}

**CLINICAL IMPLICATIONS IN PH: THERAPY**

**Inhibiting phosphodiesterases-5**

Therapies that manipulate the downstream NO signaling have revolutionized the treatment of PH (Fig. 2). Sildenafil and tadalafil are FDA approved PDE-5 inhibitors for the treatment of PAH in adults.\textsuperscript{[123-125]} The FDA recently placed a safety warning on the prescription of sildenafil, not recommending its use in pediatric patients due to increase mortality with increasing doses in this age group.\textsuperscript{[126]} This modification was based on the results of the Sildenafil Citrate in Treatment-Naive Children with Pulmonary Arterial Hypertension (STARTS-2) trial.\textsuperscript{[126]} This extension study, designed to assess the safety and tolerability of long-term treatment with oral sildenafil monotherapy in children (aged 1-17 years) with PAH, showed a higher mortality risk in patients randomized to high-dose sildenafil.\textsuperscript{[126]}

PDE-5 inhibitors prevent the normal hydrolysis of cGMP, prolonging the NO effects on tissues. PDE-5 is mainly expressed in the pulmonary vascular bed,\textsuperscript{[127]} thus its inhibition has primarily pulmonary-specific effects.\textsuperscript{[108,128]} Furthermore, PDE5 is upregulated in the lung\textsuperscript{[127]} and the hypertrophied right ventricular myocardium\textsuperscript{[129]} of patients with PAH. Therefore, PDE5 inhibitors are an ideal treatment for PAH because they decrease the right ventricular afterload and improve right ventricular inotropy, without relevant systemic hemodynamic effects.\textsuperscript{[129]}

**Using nitric oxide as an inhaled gas**

Inhaled NO was first shown to selectively reduce pulmonary vascular resistance in a lamb model;\textsuperscript{[130]} subsequently, multiple studies have confirmed this finding in humans.\textsuperscript{[118,131,132]} Continuous inhaled NO had beneficial effects in patients with PAH or PH associated with COPD;\textsuperscript{[132-134]} however, high cost and technical difficulties for its delivery and avoidance of the toxic effects of NO oxidative products have prevented its widespread use.\textsuperscript{[133]}

During continuous administration of NO, NO oxidative products (NO\textsubscript{x}) can build up and cause airway hyperactivity at low concentrations\textsuperscript{[135]} and pulmonary edema at higher concentrations.\textsuperscript{[136]} Methemoglobin is also formed as NO reacts with oxyhemoglobin. Furthermore, mechanisms should be in place to avoid abrupt cessation of inhaled NO as this may lead to rebound PAH with deleterious effects.\textsuperscript{[137,138]} Nonetheless, two studies that evaluated the long-term use (one and three months, respectively) of inhaled NO in PAH, chronic thromboembolic PH, and PH due to COPD reported no significant increase in methemoglobin, withdrawal syndrome, change in oxygenation, pulmonary function, or systemic hemodynamics.\textsuperscript{[132,134]}

Currently, inhaled NO is FDA approved for the treatment of term and near-term (>34 week gestation) neonates with hypoxic respiratory failure with clinical and echocardiographic evidence of pulmonary hypertension.\textsuperscript{[81,82,139]} Extended administration (weeks) of inhaled NO has been studied in premature infants and does not appear to improve survival or prevent bronchopulmonary dysplasia.\textsuperscript{[81,83,140,141]} At present, inhaled NO is undergoing clinical investigations to evaluate its utility as a treatment for bronchopulmonary dysplasia (NCT01503801). There are two ongoing studies using extended administration of inhaled NO in adults with PH. The PHiano study (NCT01265888, Geno LLC) is an open label, dose-escalation, Phase II study using a NO delivery system (NITROsynl) in patients with PAH or PH secondary to idiopathic pulmonary fibrosis. The second
L-arginine replacement aims at providing excess substrate for the NOS enzyme and stimulating the NO production. L-arginine attenuated PAH in different animal models of PAH\textsuperscript{153,155} and in patients with PAH associated with sickle cell disease, idiopathic PAH, and chronic thromboembolic PH.\textsuperscript{156,157} L-citrulline, a urea cycle intermediate, is metabolized to L-arginine in pulmonary vascular endothelial cells. Oral supplementation increased NO synthesis and ameliorated chronic hypoxia-induced PH in newborn piglets.\textsuperscript{159} In children undergoing cardiopulmonary bypass, the oral supplementation of L-citrulline safely increased plasma citrulline and arginine concentrations, and more importantly PH did not occur in those with elevated citrulline levels.\textsuperscript{159} The safety and effectiveness of intravenous L-citrulline, in children undergoing cardiopulmonary bypass for surgical repair of a congenital heart defect, is currently being tested (NCT01120964).

Efforts in trying to find better stability and prolonged half-life in NO delivery led to the discovery of diazeniumdiolates (diethylenetriamine/NO) that can form a group of adducts called NONOates that are complexes of NO with nucleophiles that spontaneously and nonenzymatically release NO when dissolved in aqueous neutral PH solutions. This process prolongs the half-life of NO release up to 20 hours.\textsuperscript{149,157} Nebulized NO donors have been shown to reduce PVR in hypoxia-induced PAH in piglets,\textsuperscript{148} monocrotaline rat model\textsuperscript{147} and ARDS patients\textsuperscript{149} with no systemic adverse effects or toxic reaction products of NO.

**Other therapies based on the nitric oxide pathway**
Several promising therapies which affect the signaling pathway of NO are under active investigation (Fig. 1). Soluble guanylate cyclase stimulators increase cGMP independently of NO. One of these stimulators, Riociguat, increased the activity of soluble guanylate cyclase 73-fold in vivo with partial reduction in pulmonary pressures, RV hypertrophy, and pulmonary artery muscularization in animal models of PH.\textsuperscript{150} This medication showed promising results in a Phase II study in patients with PAH and chronic thromboembolic PH.\textsuperscript{151} We are awaiting the results of two Phase III studies evaluating safety and clinical effectiveness of riociguat in PAH (NCT00810693) and chronic thromboembolic PH (NCT00855465).\textsuperscript{152} NO production by NOS depends on the de novo biosynthesis of the enzyme cofactor tetrahydrobiopterin (BH4).\textsuperscript{156,151} BH4 stabilizes the NOS dimmer assembly and the favorable spin state of the Fe (II)-O2 heme intermediate preventing “uncoupling” of the enzyme and formation of reactive oxygen products.\textsuperscript{14,162,163} The augmentation of tetrahydrobiopterin showed promising results in a pilot study in patients with PAH or chronic thromboembolic PAH.\textsuperscript{164} Another promising therapy is the recombinant human superoxide dismutase (rhSOD) that scavenges superoxide anion and increases the bioavailability of NO.\textsuperscript{165} In a lamb model of persistent PH, rhSOD administered through the endotracheal tube as a bolus enhanced the effects of inhaled NO on pulmonary vasculature.\textsuperscript{165}

Attractive new potential therapies for PAH include the NOS III enhancers, the delivery of autologous endothelial progenitor cells,\textsuperscript{166} or the enzyme NOS II and III using adenoviral-mediated transfer or adult stem cell-based ex vivo gene therapy.\textsuperscript{167} Bone marrow-derived endothelial-like progenitor cells prevented the development or progression of PH in a monocrotaline rat model of PH.\textsuperscript{168} The engraftment of these progenitor cells in the pulmonary vasculature may restore the microvascular structure and function.\textsuperscript{168} Meanwhile, animals receiving endothelial-like progenitor cells or mesenchymal stem cells transduced with NOS III had reversal of established PH and improved survival.\textsuperscript{158,169} Adenoviral gene transfer of NOS III produced an increase in the NOS III expression and activity with attenuation in the hypoxia-induced increase in pulmonary artery pressure.\textsuperscript{170} Similarly, NOS II gene transfer increased pulmonary NO production with reduction in hypoxia-induced PH and vascular remodeling in rats.\textsuperscript{171}
CONCLUSIONS

Nitric oxide mediates diverse key signaling functions in human physiology and disease. Major progress in the understanding of NO signaling pathway has led to the approval of PAH-specific treatments and the ongoing discovery and development of promising new therapies. Molecules in the NO pathway also have the potential to be used as biomarkers of disease severity, outcomes, or response to therapy in pulmonary hypertension.

REFERENCES


55. Tonelli et al.: NO deficiency in PH Pulmonary Circulation | January-March 2013 | Vol 3 | No 1


Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.


Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Care 2010;55:1623‑32.


Tonelli et al.: NO deficiency in PH


Source of Support: Dr. Adriano R. Tonelli is supported by CTSA KL2 Grant # RR024990 from the National Center for Research Resources (NCRR). Dr. Raed A. Dweik is supported by the following grants: HL081064, HL107147, HL095181, and RR026231 from the National Institutes of Health (NIH), and BRCP 08-049 Third Frontier Program grant from the Ohio Department of Development (ODOD). Dr. Metin Aytekin is supported by 0826095H from the American Heart Association (AHA). Conflict of Interest: None declared.